A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer - CA115-001
Updated: 8 February, 2023 | ClinicalTrials.gov
Print Friendly Summary
Inclusion Criteria: - Participants in all parts of the study must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. - Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. - Participants must have a life expectancy of at least 3 months at the time of first dose. Exclusion Criteria: - Untreated symptomatic central nervous system metastases or leptomeningeal metastases. - Concurrent malignancy (present during screening) requiring treatment, or history of prior malignancy active within 2 years prior to randomization in study Part B1 or treatment assignment in all other study parts. - Participants with an active, known, or suspected autoimmune disease. Other protocol-defined inclusion/exclusion criteria apply.
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
Have questions? Live support is available 24/7 - Call 855-907-3286 or email firstname.lastname@example.org